Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Antiviral drugs will initially be the mainstay of pharmaceutical intervention in an influenza pandemic. Used primarily for therapeutic treatment, they can also lower transmission in the community. We use mathematical modelling to study the impact of different antiviral coverage strategies, with a limited stockpile. Aggressive coverage offers several advantages, even if this should exhaust the stockpile prematurely. However, where a sub-group of the population has a high mortality risk, a strategy to minimise deaths must be carefully balanced, and is not always in agreement with prioritising treatment for those at risk. We discuss implications for public health planning.

Original publication

DOI

10.1016/j.epidem.2009.04.001

Type

Journal article

Journal

Epidemics

Publication Date

06/2009

Volume

1

Pages

83 - 88

Keywords

Antiviral Agents, Computer Simulation, Drug Utilization, Humans, Influenza A Virus, H5N1 Subtype, Influenza, Human, Models, Biological, Pandemics, Public Health Practice